Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody DR-0201 in a ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 24.55%, which has investors questioning if this is right time to ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

Delhi, April 04, 2025 (GLOBE NEWSWIRE) -- Over the last two decades, immunotherapy has transformed treatment strategies across various medical fields. The effectiveness of monoclonal antibodies in ...